Predictive value of AMH in late reproductive age: a retrospective cohort study
- PMID: 40596221
- PMCID: PMC12217941
- DOI: 10.1038/s41598-025-07411-w
Predictive value of AMH in late reproductive age: a retrospective cohort study
Abstract
This study evaluates the predictive value of Anti-Müllerian Hormone (AMH) levels on outcomes in medically assisted reproduction (MAR), with a focus on women of late reproductive age. AMH, produced by granulosa cells in ovarian follicles, serves as an important indicator of ovarian reserve. A retrospective cohort analysis was conducted, encompassing 4891 MAR cycles, to assess the age-specific predictive value of AMH for clinical pregnancy. The results indicate that AMH is significantly correlated with clinical pregnancy outcomes (p < 0.01) and demonstrates potential predictive value in women over 35 years of age, with its predictive capacity increasing notably with age (AUC = 0.62-0.69). However, in younger women, the correlation between AMH levels and MAR outcomes is weaker (AUC = 0.48-0.53). These findings highlight the importance of integrating AMH measurements with age when assessing fertility potential and tailoring MAR treatments, particularly for women approaching the end of their reproductive lifespan.
Keywords: AMH; Clinical pregnancy; IVF; Late reproductive age; MAR.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval: Use of the database was approved by the Medical Ethics Committee of UKC Maribor under approval number UKC-MB-KME-48/24.
Figures
Similar articles
-
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD012693. doi: 10.1002/14651858.CD012693.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2024 Jan 4;1:CD012693. doi: 10.1002/14651858.CD012693.pub3. PMID: 29388198 Free PMC article. Updated.
-
The role of anti-Müllerian hormone: insights into ovarian reserve, primary ovarian insufficiency, and menopause prediction.Endocrine. 2025 Aug;89(2):338-355. doi: 10.1007/s12020-025-04265-0. Epub 2025 May 23. Endocrine. 2025. PMID: 40410629 Free PMC article. Review.
-
Evaluating serum anti-Müllerian hormone as a diagnostic biomarker for polycystic ovary syndrome in Pakistani women.Int J Gynaecol Obstet. 2025 Jun 25. doi: 10.1002/ijgo.70240. Online ahead of print. Int J Gynaecol Obstet. 2025. PMID: 40560122
-
Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.Arch Gynecol Obstet. 2023 Jul;308(1):43-61. doi: 10.1007/s00404-022-06683-1. Epub 2022 Jul 30. Arch Gynecol Obstet. 2023. PMID: 35907969
-
Cumulative ongoing pregnancy and live birth rates after assisted reproduction among women with diminished ovarian reserve: A multi-institutional retrospective cohort study.J Obstet Gynaecol Res. 2025 Jun;51(6):e16336. doi: 10.1111/jog.16336. J Obstet Gynaecol Res. 2025. PMID: 40545811
References
-
- Clemente, N. D., Racine, C., Pierre, A. & Taieb, J. Anti-Müllerian hormone in female reproduction. Endocr. Rev.11(42), 753–782. 10.1210/endrev/bnab012 (2021). - PubMed
-
- Penzias, A. et al. Testing and interpreting measures of ovarian reserve: A committee opinion. Fertil. Steril.12(114), 1151–1157. 10.1016/j.fertnstert.2020.09.134 (2020). - PubMed
-
- Tal, R. et al. AMH highly correlates with cumulative live birth rate in women with diminished ovarian reserve independent of age. J. Clin. Endocrinol. Metab.8(106), 2754–2766. 10.1210/clinem/dgab168 (2021). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources